Wellness peptides like BPC-157 and TB-500 are exploding in popularity, with bold claims around recovery, longevity, and performance. But how much of that promise is actually backed by human data? In this episode, we sit down with drug development expert Dr. Leigh Baxt to separate what we know from what we still don't.
Leigh takes us behind the scenes of how therapeutics actually move from promising science to approved medicine, and why that process matters when evaluating today's peptide boom. We unpack the gaps in research, potential risks, gray-market sourcing, and what physicians should know when patients come asking about wellness peptides.
Podden och tillhörande omslagsbild på den här sidan tillhör
Jake Wright & Dr. Suzanne Rutherford. Innehållet i podden är skapat av Jake Wright & Dr. Suzanne Rutherford och inte av,
eller tillsammans med, Poddtoppen.